Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

BMC Urology

Research Article

Alba Aguado-Jodar¹  Jordi Ibáñez-Nolla²  Antoni Sicras-Mainar³  Marion Kvasz⁴  Javier Rejas⁵  Ruth Navarro-Artieda⁶  Amador Ruiz-Torrejón⁷ 

[1] CAP Sagrada Familia, Barcelona, Spain;Directorate of Badalona Serveis Assistencials SA, Hospital Municipal de Badalona, Badalona, Barcelona, Spain;Directorate of Planning, Badalona Serveis Assistencials SA, Calle Gaietà Soler, 6-8 entlo, CP 08911, Badalona, Barcelona, Spain;Health Economics and Outcomes Research, Pfizer PIO, Paris, France;Health Economics and Outcomes Research, Pfizer SLU, Alcobendas, Madrid, Spain;Medical Information Department, Hospital Germans Trias i Pujol, Badalona, Spain;Primary Health Care Directorate, 1ib-Salut, Mallorca, Spain;

关键词: Antimuscarinics;    Overactive bladder;    Costs;    Primary care setting;    Health resources;   

DOI  :  10.1186/1471-2490-13-51

 received in 2013-06-25, accepted in 2013-10-11,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundOveractive bladder (OAB) is associated with high healthcare costs, which may be partially driven by drug treatment. There is little comparative data on antimuscarinic drugs with respect to resource use and costs. This study was conducted to address this gap and the growing need for naturalistic studies comparing health economics outcomes in adult patients with OAB syndrome initiating treatment with different antimuscarinic drugs in a primary care setting in Spain.MethodsMedical records from the databases of primary healthcare centres in three locations in Spain were assessed retrospectively. Men and women ≥18 years of age who initiated treatment with fesoterodine, tolterodine or solifenacin for OAB between 2008 and 2010 were followed for 52 weeks. Healthcare resource utilization and related costs in the Spanish National Health System were compared. Comparisons among drugs were made using multivariate general linear models adjusted for location, age, sex, time since diagnosis, Charlson comorbidity index, and medication possession ratio.ResultsA total of 1,971 medical records of patients (58.3% women; mean age, 70.1 [SD:10.6] years) initiating treatment with fesoterodine (n = 302), solifenacin (n = 952) or tolterodine (n = 717) were examined. Annual mean cost per patient was €1798 (95% CI: €1745; €1848). Adjusted mean (95% bootstrap CI) healthcare costs were significantly lower in patients receiving fesoterodine (€1639 [1542; 1725]) compared with solifenacin (€1780 [€1699; €1854], P = 0.022) or tolterodine (€1893 [€1815; €1969], P = 0.001). Cost differences occurred because of significantly fewer medical visits, and less use of absorbent products and OAB-related concomitant medication in the fesoterodine group.ConclusionsCompared with solifenacin and tolterodine, fesoterodine was a cost-saving therapy for treatment of OAB in the primary care setting in Spain.

【 授权许可】

CC BY   
© Sicras-Mainar et al.; licensee BioMed Central Ltd. 2013